Shanghai Key Laboratory for Molecular Imaging, Collaborative Research Center, Shanghai University of Medicine and Health Sciences, Shanghai, China; Department of Liver Surgery, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Department of Transplantation, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Cell Mol Gastroenterol Hepatol. 2019;7(3):623-639. doi: 10.1016/j.jcmgh.2018.12.009. Epub 2019 Jan 7.
BACKGROUND & AIMS: Chemokine-mediated immune cell recruitment plays pivotal roles in liver inflammation. C-C motif chemokine ligand 5 (CCL5) has been shown to be responsible for the recruitment of monocytes/macrophages and has been implicated in various liver diseases, including nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. Previous studies have also shown that inhibition of CCL5 appears to be a promising therapeutic approach for several chronic liver diseases. However, whether blocking CCL5 could benefit immune cell-mediated hepatitis remains largely elusive.
By adopting a specific agonist, alpha-galactosylceramide (α-Galcer), of invariant natural killer T cells (iNKTs), we investigated the function and mechanism of CCL5 in the iNKT induced murine hepatitis model.
We found significantly increased CCL5 expression in α-Galcer-induced hepatitis murine model. Such an increase in CCL5 is mainly enriched in non-parenchymal cells such as macrophages and iNKTs but not in hepatocytes. Surprisingly, CCL5 blockage by genetic deletion of Ccl5 does not affect the α-Galcer-induced iNKT activation but greatly worsens α-Galcer-induced liver injury accompanied by an increased hepatic neutrophil infiltration. Mechanistically, we demonstrated that greater neutrophil accumulation in the liver is responsible for the enhanced liver injury in Ccl5 mice. Such an increased hepatic neutrophil infiltration is mainly caused by an enhanced CXCL1-CXCR2 signal in Ccl5 mice. Therapeutically, either antibody-mediated neutrophil depletion or a CXCR2 antagonist, SB225002, mediated CXCR2 signaling blockage significantly ameliorated α-Galcer-induced liver injury in Ccl5 mice.
Our present study demonstrates that (1) α-Galcer-induced murine hepatitis could greatly induce CCL5 production in macrophages and iNKT cells; (2) loss of CCL5 could enhance CXCL1 expression in hepatocytes and activate CXCL1-CXCR2 axis in neutrophils to augment their hepatic infiltration; and (3) neutrophil depletion or blockage of CXCL1-CXCR2 axis greatly improves α-Galcer-induced liver injury in Ccl5 mice. This study suggests that clinical utilization of CCL5 blockage may compensatorily induce the activation of other chemokine pathways to enhance neutrophil recruitment and liver injury in hepatitis.
趋化因子介导的免疫细胞募集在肝脏炎症中起着关键作用。趋化因子 C-C 基序配体 5(CCL5)已被证明负责招募单核细胞/巨噬细胞,并与各种肝病有关,包括非酒精性脂肪性肝病、纤维化和肝细胞癌。先前的研究还表明,抑制 CCL5 似乎是治疗几种慢性肝病的一种有前途的方法。然而,阻断 CCL5 是否有益于免疫细胞介导的肝炎在很大程度上仍不清楚。
通过采用特异性激动剂α-半乳糖神经酰胺(α-Galcer)来激活固有自然杀伤 T 细胞(iNKT),我们研究了 CCL5 在 iNKT 诱导的小鼠肝炎模型中的功能和机制。
我们发现α-Galcer 诱导的肝炎小鼠模型中 CCL5 的表达显著增加。这种 CCL5 的增加主要富集在非实质细胞如巨噬细胞和 iNKT 中,而不是在肝细胞中。令人惊讶的是,通过基因敲除 Ccl5 阻断 CCL5 并不影响 α-Galcer 诱导的 iNKT 激活,但会大大加重 α-Galcer 诱导的肝损伤,伴有肝中性粒细胞浸润增加。在机制上,我们证明了肝脏中更多的中性粒细胞聚集是导致 Ccl5 小鼠肝损伤加重的原因。在 Ccl5 小鼠中,这种肝中性粒细胞浸润的增加主要是由于 Ccl5 小鼠中 CXCL1-CXCR2 信号的增强所致。在治疗上,抗体介导的中性粒细胞耗竭或 CXCR2 拮抗剂 SB225002 阻断 CXCR2 信号均能显著改善 Ccl5 小鼠的 α-Galcer 诱导的肝损伤。
本研究表明:(1)α-Galcer 诱导的小鼠肝炎可大大诱导巨噬细胞和 iNKT 细胞中 CCL5 的产生;(2)CCL5 的缺失可增强肝细胞中 CXCL1 的表达,并激活中性粒细胞中的 CXCL1-CXCR2 轴,从而增加其肝内浸润;(3)中性粒细胞耗竭或阻断 CXCL1-CXCR2 轴可显著改善 Ccl5 小鼠的 α-Galcer 诱导的肝损伤。该研究提示,临床应用 CCL5 阻断可能会代偿性地激活其他趋化因子途径,以增强中性粒细胞募集和肝炎中的肝损伤。